State Street’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-823,111
| Closed | -$1.31M | – | 4455 |
|
|
2024
Q1 | $1.31M | Buy |
823,111
+712
| +0.1% | +$1.06K | ﹤0.01% | 3401 |
|
|
2023
Q4 | $706K | Buy |
822,399
+27,876
| +4% | +$24.5K | ﹤0.01% | 3560 |
|
|
2023
Q3 | $850K | Sell |
794,523
-62,043
| -7% | -$128K | ﹤0.01% | 3568 |
|
|
2023
Q2 | $2.22M | Buy |
856,566
+117,214
| +16% | +$418K | ﹤0.01% | 3358 |
|
|
2023
Q1 | $3.02M | Buy |
739,352
+34,801
| +5% | +$161K | ﹤0.01% | 3178 |
|
|
2022
Q4 | $3.54M | Sell |
704,551
-151,024
| -18% | -$947K | ﹤0.01% | 3187 |
|
|
2022
Q3 | $11.2M | Buy |
855,575
+85,133
| +11% | +$1.29M | ﹤0.01% | 2638 |
|
|
2022
Q2 | $9.88M | Buy |
770,442
+78,936
| +11% | +$1.09M | ﹤0.01% | 2729 |
|
|
2022
Q1 | $10.5M | Buy |
691,506
+16,126
| +2% | +$252K | ﹤0.01% | 2798 |
|
|
2021
Q4 | $12M | Buy |
675,380
+54,217
| +9% | +$1.04M | ﹤0.01% | 2814 |
|
|
2021
Q3 | $13.1M | Buy |
621,163
+26,545
| +4% | +$584K | ﹤0.01% | 2726 |
|
|
2021
Q2 | $11.7M | Buy |
594,618
+106,936
| +22% | +$2.5M | ﹤0.01% | 2823 |
|
|
2021
Q1 | $14.2M | Buy |
487,682
+22,479
| +5% | +$629K | ﹤0.01% | 2564 |
|
|
2020
Q4 | $14.1M | Buy |
465,203
+23,503
| +5% | +$514K | ﹤0.01% | 2441 |
|
|
2020
Q3 | $7.03M | Sell |
441,700
-22,926
| -5% | -$418K | ﹤0.01% | 2631 |
|
|
2020
Q2 | $9.17M | Buy |
464,626
+5,574
| +1% | +$107K | ﹤0.01% | 2462 |
|
|
2020
Q1 | $5.66M | Buy |
459,052
+82,379
| +22% | +$1.34M | ﹤0.01% | 2566 |
|
|
2019
Q4 | $6.96M | Buy |
376,673
+246,853
| +190% | +$3.61M | ﹤0.01% | 2692 |
|
|
2019
Q3 | $1.8M | Buy |
129,820
+40,725
| +46% | +$611K | ﹤0.01% | 3253 |
|
|
2019
Q2 | $732K | Buy |
+89,095
| New | +$1.3M | ﹤0.01% | 3465 |
|
State Street's NGM Position: Q2 2024 in Review
State Street sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 823,111 shares — an estimated $1.31M sold.
State Street first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $14.2M in Q1 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- State Street reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- State Street sold 823,111 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.31M.
- State Street first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- State Street's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $14.2M in Q1 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.